Pliant Therapeutics (PLRX) Total Liabilities (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Total Liabilities of $37.4 million for Q1 2026, down 57.27% year-over-year from $87.6 million in Q1 2025, and down 14.98% quarter-over-quarter from $44.0 million in Q4 2025.
Pliant Therapeutics (PLRX) Total Liabilities (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Total Liabilities for 8 consecutive years, with $37.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 57.27% year-over-year to $37.4 million; the TTM figure through Mar 2026 stood at $37.4 million (down 57.27% YoY), while the FY2025 annual figure was $44.0 million, down 52.6% from the prior year.
- Total Liabilities fell to $37.4 million in Q1 2026 per PLRX's latest filing, from $44.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $99.8 million in Q3 2024 and bottomed at $23.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $57.9 million across 5 years, with a median of $41.8 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 213.83% — and 2026, when it sank 57.27%.
- Pliant Therapeutics' Total Liabilities stood at $37.3 million in 2022, then advanced by 3.51% to $38.6 million in 2023, then soared by 140.73% to $92.9 million in 2024, then tumbled by 52.6% to $44.0 million in 2025, then slipped by 14.98% to $37.4 million in 2026.
- Business Quant data shows PLRX's Total Liabilities at $37.4 million in Q1 2026, $44.0 million in Q4 2025, and $76.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 10.03 Bn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | 42.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.96 Mn |
| Mar 31, 2026 | 37.43 Mn |
| Dec 31, 2025 | 44.02 Mn |
| Sep 30, 2025 | 76.29 Mn |
| Jun 30, 2025 | 79.74 Mn |
| Mar 31, 2025 | 87.61 Mn |
| Dec 31, 2024 | 92.87 Mn |
| Sep 30, 2024 | 99.84 Mn |
| Jun 30, 2024 | 91.05 Mn |
| Mar 31, 2024 | 84.27 Mn |
| Dec 31, 2023 | 38.58 Mn |
| Sep 30, 2023 | 37.42 Mn |
| Jun 30, 2023 | 41.83 Mn |
| Mar 31, 2023 | 35.96 Mn |
| Dec 31, 2022 | 37.27 Mn |
| Sep 30, 2022 | 40.19 Mn |
| Jun 30, 2022 | 36.83 Mn |
| Mar 31, 2022 | 23.23 Mn |
| Dec 31, 2021 | 22.16 Mn |
| Sep 30, 2021 | 13.68 Mn |